公开(公告)号：US20240311038A1

公开(公告)日：2024-09-19

申请号：US18406997

申请日：2024-01-08

Applicant: University of Central Florida Research Foundation, Inc. ,  Board of Regents, University of Texas System

Inventor： Rickard Ewetz ,  Sven Thijssen ,  Sumit Kumar Jha

IPC: G06F3/06

CPC classification number: G06F3/0655 ,  G06F3/0604 ,  G06F3/0653 ,  G06F3/0679

Abstract: A system and method for evaluating Boolean functions using in-memory computing comprising a plurality of programmed non-volatile memory devices synthesized in a crossbar design. The evaluation phase of a given Boolean function using the programmed non-volatile memory devices is accomplished using READ operations only.

公开(公告)号：US10329326B2

公开(公告)日：2019-06-25

申请号：US15263028

申请日：2016-09-12

Applicant: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. ,  INTEZYNE TECHNOLOGIES INC. ,  ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA ,  BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM

Inventor： Robert J. Gillies ,  David L. Morse ,  Natalie M. Barkey ,  Kevin N. Sill ,  Josef Vagner ,  Narges K. Tafreshi ,  Jonathan L. Sessler ,  Christian Preihs ,  Victor J. Hruby

IPC: A61K38/00 ,  C07K5/117 ,  C07K14/68 ,  A61K49/00 ,  A61K49/10 ,  A61K49/18 ,  C07K7/08 ,  C07K14/72 ,  A61K47/64 ,  A61K47/69 ,  A61K38/34

Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.

公开(公告)号：US10208059B2

公开(公告)日：2019-02-19

申请号：US15285177

申请日：2016-10-04

Applicant: Board of Regents, University of Texas System

Inventor： Philip Jones ,  Maria Emilia Di Francesco ,  Alessia Petrocchi ,  Christopher L. Carroll ,  Joe Marszalek ,  Barbara Czako ,  Ryan Johnson ,  Jay Theroff

IPC: C07D413/14 ,  C07D495/04 ,  C07D413/04 ,  C07D417/14 ,  C07D417/04 ,  A61K45/06 ,  A61K31/496 ,  A61K31/454 ,  C07D471/04 ,  C07D513/04 ,  A61K31/4245 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  C07D405/14 ,  A61K31/427 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/506

Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.

公开(公告)号：US20170169178A1

公开(公告)日：2017-06-15

申请号：US15116994

申请日：2015-02-06

Applicant: Home Base Impairment Company, Inc. ,  Board of Regents, University of Texas System

Inventor： Pamela J. Beehler ,  Clarence W. Carlos, II ,  Mark A. Cavicchia ,  Paul S. Chirgott ,  Michael A. Hauser ,  George V. Kondraske

IPC: G06F19/00

CPC classification number: G16H50/30

Abstract: The invention relates to computer-based methods, systems, and mediums for identifying a change to the cumulative characterization of certain brain performance data collected from an individual, wherein the collected brain performance data is directly related to how at least one of the individual's neuromotor or cognitive brain functions is performing, hereinafter such a cumulative characterization is referred to as the individual's “Brain Performance Profile”. The computer-based methods, systems, and mediums of the present invention identify and monitor changes in an individual's Brain Performance Profile by employing a computer system which is programmed and configured to perform at least the following tasks: to compute an individual's Normal Brain Performance Profile through the implementation of a test session taken at least two separate times; to compute the individual's Current Brain Performance Profile through the implementation of the test session taken at a time after their Normal Brain Performance Profile has been computed; and, to calculate whether a change to the individual's Brain Performance Profile has occurred through a mathematical manipulation of their Normal Brain Performance Profile and their Current Brain Performance Profile.

公开(公告)号：US09663504B2

公开(公告)日：2017-05-30

申请号：US14631454

申请日：2015-02-25

Applicant: Board of Regents, University of Texas System

Inventor： Philip Jones ,  Maria Emilia Di Francesco ,  Timothy McAfoos

IPC: C07D413/14

CPC classification number: A61K31/454 ,  A61K31/4245 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/541 ,  C07D413/14

Abstract: The present disclosure relates to salts of heterocyclic compounds and methods that inhibit HIF pathway activity. The compounds are designed to treat or prevent cancer and other hypoxia-mediated diseases.

公开(公告)号：US20170121342A1

公开(公告)日：2017-05-04

申请号：US15285177

申请日：2016-10-04

Applicant: Board of Regents, University of Texas System

Inventor： Philip Jones ,  Maria Emilia Di Francesco ,  Alessia Petrocchi ,  Christopher L. Carroll ,  Joe Marszalek ,  Barbara Czako ,  Ryan Johnson ,  Jay Theroff

IPC: C07D495/04 ,  A61K31/496 ,  C07D405/14 ,  A61K31/4439 ,  A61K31/4545 ,  C07D413/04 ,  A61K31/5377 ,  C07D471/04 ,  A61K31/437 ,  C07D417/14 ,  A61K31/427 ,  A61K31/506 ,  A61K31/541 ,  A61K31/519 ,  A61K31/497 ,  C07D417/04 ,  A61K31/4709 ,  C07D413/14

CPC classification number: C07D495/04 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D513/04

Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.

公开(公告)号：US09353094B2

公开(公告)日：2016-05-31

申请号：US14639501

申请日：2015-03-05

Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA ,  THE BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM

Inventor： Amarnath Natarajan ,  Qianyi Chen ,  Vashti C. Bryant ,  Rajkumar Rajule

IPC: C07D241/44 ,  C07D409/14 ,  C07D241/42 ,  C07D405/04 ,  C07D405/14 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D471/04

CPC classification number: C07D409/14 ,  C07D241/42 ,  C07D241/44 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/04 ,  C07D405/14 ,  C07D471/04

Abstract: Disclosed herein are compounds of formula (I) and methods of inhibiting IKKβ and the NF-κB signaling and mTOR pathways.

Abstract translation: 本文公开了式（I）的化合物和抑制IKK和bgr的方法; 和NF-κB信号通路和mTOR通路。

公开(公告)号：US20020159998A1

公开(公告)日：2002-10-31

申请号：US10086217

申请日：2002-02-21

Applicant: Board of Regents, University of Texas System

Inventor： Gregory R. Mundy ,  Toshiyuki Yoneda

IPC: A61K039/395

CPC classification number: C07K14/70542 ,  A61K38/00 ,  C07K16/2836 ,  C07K16/2839 ,  C07K16/2842

Abstract: Antagonists of null4 integrin/null4 integrin ligand adhesion, which inhibit the biological effects of such adhesion are described and methods for their use are detailed. Such antagonists are useful in suppressing bone destruction associated with multiple myeloma. The homing of multiple myeloma cells to bone marrow and their null4 integrin-dependent release of bone-resorbing factors, resulting in bone destruction in patients with multiple myeloma, is inhibited.

公开(公告)号：US20020052332A1

公开(公告)日：2002-05-02

申请号：US09832611

申请日：2001-04-11

Applicant: The Board of Regents, University of Texas System

Inventor： Bernard F. Godley

IPC: A61K031/70 ,  A01N043/04 ,  C12P021/06 ,  C12N015/00 ,  C12N015/09 ,  C12N015/63 ,  C12N015/70 ,  C12N015/74

CPC classification number: C12N9/1088 ,  A61K31/70 ,  A61K48/00

Abstract: The present invention provides methods for inhibiting the degeneration of retinal pigment epithelial cells, which can reduce the incidence of, or delay the onset of, age-related macular degeneration, particularly in the early stages of AMD or in individuals at high risk for the disease.

Abstract translation: 本发明提供抑制视网膜色素上皮细胞变性的方法，其可以降低年龄相关性黄斑变性的发生率或延迟发作，特别是在AMD的早期阶段或患有该疾病的高风险个体中 。

公开(公告)号：US20020041874A1

公开(公告)日：2002-04-11

申请号：US09943659

申请日：2001-08-31

Applicant: The Board of Regents, University of Texas System

Inventor： Gregory R. Mundy ,  Toshiyuki Yoneda

IPC: A61K039/395

CPC classification number: C07K14/70542 ,  A61K38/00 ,  C07K16/2836 ,  C07K16/2839 ,  C07K16/2842

Abstract: Antagonists of null4 integrin/null4 integrin ligand adhesion, which inhibit the biological effects of such adhesion are described and methods for their use are detailed. Such antagonists are useful in suppressing bone destruction associated with multiple myeloma. The homing of multiple myeloma cells to bone marrow and their null4 integrin-dependent release of bone-resorbing factors, resulting in bone destruction in patients with multiple myeloma, is inhibited.

Abstract translation: 描述了抑制这种粘附的生物学作用的α4整联蛋白/α4整联蛋白配体粘附的拮抗剂，并详细说明了其使用方法。 这样的拮抗剂可用于抑制与多发性骨髓瘤相关的骨破坏。 多发性骨髓瘤细胞归巢到骨髓及其α4整联蛋白依赖性释放的骨吸收因子，导致多发性骨髓瘤患者骨质破坏。